United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

Exelixis

Merck

Novartis

Kidney-Cancer Market: Good for Patients, Hard for Investors

Exact Sciences

Here's why Cologuard's popularity will continue to climb for a long time.

Exact Sciences Is Near an All-Time High: Here's Why It Could Go Even Higher

Eli Lilly

Eli Lilly And Co (NYSE: LLY) faced a setback following the  release of top-line results from a late-stage study of its pain medication candidate.

Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns

AbbVie

Intercept Pharma

Vertex Pharmaceuticals

Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.

5 Top Pharmaceutical Stocks to Buy in 2019

Shares of drug makers Pfizer Inc. and Eli Lilly & Co. declined in the extended session Thursday after the companies said a clinical study of an osteoarthritis drug didn't meet certain goals.

Pfizer, Lilly shares decline as osteoarthritis drug misses goals in study

Here's what could get in the way of the big pharma company's future success.

The 3 Greatest Risks Pfizer Faces

Historical and projected rates of return for Johnson & Johnson are compared to similar data for Pfizer - with Pfizer, perhaps surprisingly, coming out a clear winner.

Pfizer: A Better Prospect

Pfizer closed the most recent trading day at $42.73, moving -0.26% from the previous trading session.

Pfizer Stock Sinks As Market Gains: What You Should Know

Supported by large share repurchases, Pfizer share price has shown steady growth, from ~$25 in 2012 to the current level.

Pfizer: Solid, Stable Returns

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components.

The 5 Most Shorted Dow Stocks: Pfizer

Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.

Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men

Sangamo Therapeutics

Sangamo Therapeutics popped to a five-month high Tuesday after its gene-editing therapy showed promise as a hemophilia A treatment. Sangamo stock jumped by double digits in high volume.

Gene-Editing Biotechs Pop After Pfizer Partner Scores In Hemophilia A

Large-cap pharma stocks have seen a mixed performance in year to date, and among this group, Pfizer Inc.  is poised to benefit from some key second-half catalysts, according to an analyst at Bank of America Merrill Lynch.

Bank Of America Hikes Pfizer Price Target, Estimates Citing Orphan Drug Catalysts

The Dow is having its best start to the year since 2013. Now, two market watchers agree that one of the Dow components is a compelling name to own if you want to play catch-up: Pfizer.

This Dow stock could be a way to play catch-up to the rally

Shares of drug giant Pfizer Inc.have been lagging rival Merck & Co., Inc.. The gain of 23% for Pfizer from this time a year ago is an impressive 23% return, but Merck’s gain has been 55% in the same period

Why Pfizer May Soon Make Up Lost Ground in Underperforming Against Merck

Royal Bank of Canada

Simon Property Group

AT&T

24/7 Wall St. screened the portfolio looking for the highest yielding Buy rated companies and found five from different sectors that are solid plays now.

5 Must-Own Merrill Lynch Income Portfolio High-Dividend Stocks

Pfizer Inc. said Wednesday it has paid 45 million euro, or the equivalent of $51 million to acquire a 15% equity stake in privately held gene therapy company Vivet Therapeutics.

Pfizer acquires option to buy Vivet Therapeutics for equivalent of $635.8 million

Pfizer Inc said on Wednesday it has acquired a 15 percent stake in Vivet Therapeutics, and has an exclusive option to fully acquire the privately held French company that develops gene therapies for liver disorders.

Pfizer buys stake in French gene therapy firm Vivet

Activision Blizzard

NIKE

The first stock you ever buy could be the most important. These three names won't disappoint.

Stocks to Build Your Portfolio Around

Pfizer’s oncology business contributes more than 10% to its overall top line. This can be attributed to its breast cancer drug ~ Ibrance ~ which has been doing well of late, and it has a large addressable market.

How Important Is Oncology For Pfizer?

Apple

Boeing

Cisco Systems

Disney

Intel

Microsoft

UnitedHealth Group

Walmart

A year ago, I introduced to Forbes readers my Dobermans of the Dow screen. It's simple to employ, and the historical returns far exceed the traditional Dogs of the Dow.

Forget About Dogs Of The Dow In 2019, Upgrade To Dobermans

News for Pfizer Stock (PFE)